- Home
- ZBRA vs PODD Comparison
ZBRA vs PODD Comparison
Compare ZBRA & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBRA | PODD |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 10.3B |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ZBRA | PODD |
|---|---|---|
| Price | $249.67 | $157.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $321.88 | ★ $341.48 |
| AVG Volume (30 Days) | 887.7K | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.72 | 1.30 |
| Revenue | ★ $5,396,000,000.00 | $2,708,100,000.00 |
| Revenue This Year | $13.27 | $24.55 |
| Revenue Next Year | $5.43 | $19.18 |
| P/E Ratio | ★ $89.49 | $118.32 |
| Revenue Growth | 8.33 | ★ 30.73 |
| 52 Week Low | $199.05 | $138.79 |
| 52 Week High | $352.66 | $354.88 |
Technical Indicators
Market Signals| Indicator | ZBRA | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 55.15 |
| Support Level | $234.39 | $143.11 |
| Resistance Level | $268.59 | $161.35 |
| Average True Range (ATR) | 10.73 | 6.01 |
| MACD | 1.26 | 1.93 |
| Stochastic Oscillator | 91.80 | 83.13 |
Price Performance
Historical ComparisonAbout ZBRA Zebra Technologies Corporation
Zebra Technologies is the largest provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.